Moreover, combining DHHC9 inhibitors with existing targeted therapies or immunotherapies could provide synergistic effects, potentially overcoming resistance mechanisms and improving clinical outcomes in metastatic cancer. This evidence concerns the gene ZDHHC9 and metastatic malignant neoplasm.